Adjuvant therapy of secondary peritonitis by taurolidine may modulare the systemic cytoline-mediated host response;ADJUVANTE PERITONITISTHERAPIE MIT TAUROLIDIN MODULATION DER MEDIATORFREISETZUNG

Langenbecks Archiv fur Chirurgie

Volumn 382, Issue 4 SUPPL.1, 1997, Pages

  Staubach, K H ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Compartimentalization; Mediators; Peritonitis; Sepsis; Systemic inflammatory response syndrome

Indexed keywords

TAUROLIDINE;

ADJUVANT THERAPY; CONFERENCE PAPER; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PERITONITIS;

EID: 0031441398     PISSN: 00238236     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00014640     Document Type: Conference Paper

References (17)

1. Ahrenholz DH, Simmons RL ( 1980) Fibrin in peritonitis: I. Beneficial and adverse effects of fibrin in experimental E. coli peritonitis. Surgery 88:41
2. Astiz ME, Saha DC, Carpati CM, Rackow EC (1994) Induction of endotoxintolerance with monophosphoryt lipid A in peritonitis: importance of localized therapy. J Lab Clin Med 123:89
3. Bedrosian I, Sofia RD, Wolff SM, Dinarello CA (1991) Taurolidine an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine 3:568
4. Blenkharn JI (1987) The antibacterial and anti-endotoxin activity of taurolidine in combination with antibiotics. Surg Res Commun 2:149
5. Blenkharn JI (1988) Sustained anti-adherence activity of taurolidine (Taurolin) and noxythiolin (Noxyflex S) solutions. J Pharm Pharmacol 40:509
6. Bone R (1996) Towards a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 24: 163
7. Echternacher B, Falk W, Mannel DN, Krammer PH (1990) Requirement of endogenous tumor necrosis factor cachectin for recovery from experimental peritonitis. J Immunol 145:3762
8. Hau T, Ahrenholz DH, Simmons RL (1979) Secondary bacterial peritonitis: the biological basis of treatment. Curr Probl Surg 16:1
9. Holzheimer RG, Schein M, Wittmann DH ( 1995) Inflammatory response in peritoneal exudate and plasma of patients undergoing planned relaparotomy of severe secondary peritonitis. Arch Surg 130:1314
10. Kuraoka S, Campeau JD, Nakamura RM, DiZerega GS (1992) Modulation of postsurgical macrophage function by early postsurgical polymorphonuclear leucocytes. J Surg Res 53:245
11. Maddaus MA, Ahrenholz DH, Simmons RL (1988) The biology of peritonitis and implications for treatment. Surg Clin North Am 68:431
12. Natanson C, Hoffmann WD, Suffredini AF, Eichacker Q, Danner B, L (1994) Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 120:771
13. Rosman C, Westerveld GJ, Oeveren W van, Kooi K, Bleichrodt RP (1996) Effect of intraperitoneal anti-microbials on the concentration of bacteria, endotoxin and tumor necrosis factor in abdominal fluid and plasma in rats. Eur Surg Res 28:351
14. Schein M, Wittmann DH, Holzheimer RG, Condon RE (1996) Hypothesis: compartementalization of cytokines in intraabdominal infection. Surgery 119:694
15. Shapiro L, Gelfand JA (1993) Cytokines and sepsis: pathology and therapy. New Horiz 1:13
16. Staubach KH (1993) Die Lokalbehandlung der Peritonitis. Aktuelle Chir 28:128
17. Syala A, Kirsala JM, Felt JA, Perin MM, Chaudry IH (1992) Does endotoxin tolerance prevent the release of inflammatory monokines (interleukin 1, interleukin 6 or tumor necrosis factor) during sepsis. Adv Surg 127:191